UniSa - IRIS Institutional Research Information System

PAPACCIO, Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.113
NA - Nord America 1.376
EU - Europa 492
SA - Sud America 244
AF - Africa 30
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.261
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 3.126
US - Stati Uniti d'America 1.334
SG - Singapore 496
BR - Brasile 183
RU - Federazione Russa 130
VN - Vietnam 126
CN - Cina 124
IT - Italia 117
FR - Francia 64
BD - Bangladesh 63
KR - Corea 53
DE - Germania 41
IE - Irlanda 31
GB - Regno Unito 26
AR - Argentina 24
IN - India 24
NL - Olanda 23
CA - Canada 18
IQ - Iraq 15
MX - Messico 15
JP - Giappone 14
UA - Ucraina 12
TR - Turchia 11
CO - Colombia 10
AT - Austria 9
ID - Indonesia 9
ES - Italia 8
UZ - Uzbekistan 8
VE - Venezuela 8
ZA - Sudafrica 7
BE - Belgio 6
PK - Pakistan 6
FI - Finlandia 5
KE - Kenya 5
PL - Polonia 5
DZ - Algeria 4
EC - Ecuador 4
GE - Georgia 4
JO - Giordania 4
MA - Marocco 4
MY - Malesia 4
PH - Filippine 4
AU - Australia 3
AZ - Azerbaigian 3
BO - Bolivia 3
CL - Cile 3
NP - Nepal 3
PE - Perù 3
RO - Romania 3
BH - Bahrain 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
EE - Estonia 2
EG - Egitto 2
HU - Ungheria 2
LK - Sri Lanka 2
PA - Panama 2
PY - Paraguay 2
SA - Arabia Saudita 2
SE - Svezia 2
TH - Thailandia 2
TW - Taiwan 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
BW - Botswana 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GA - Gabon 1
GP - Guadalupe 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
IL - Israele 1
KH - Cambogia 1
KI - Kiribati 1
KZ - Kazakistan 1
LB - Libano 1
ML - Mali 1
MR - Mauritania 1
NA - Namibia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PT - Portogallo 1
RS - Serbia 1
SR - Suriname 1
TT - Trinidad e Tobago 1
Totale 6.261
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.125
San Jose 265
Singapore 235
Dallas 138
Ashburn 131
Chandler 128
Princeton 95
Council Bluffs 82
Lauterbourg 61
Moscow 54
The Dalles 47
Ho Chi Minh City 46
Hanoi 30
Dublin 29
Andover 24
Redwood City 23
New York 18
Wilmington 18
Beijing 17
Naples 16
Amsterdam 15
Ann Arbor 15
Santa Clara 14
Tokyo 14
Frankfurt am Main 13
Los Angeles 13
São Paulo 12
Nuremberg 11
Da Nang 10
San Francisco 9
Seattle 9
Buffalo 8
Seoul 8
Tashkent 8
Baghdad 7
Curitiba 7
Dhaka 7
Montreal 7
Washington 7
Johannesburg 6
Sarno 6
Toronto 6
Vienna 6
Brooklyn 5
Caracas 5
Istanbul 5
Medellín 5
Milan 5
Munich 5
Rome 5
Amman 4
Atlanta 4
Boston 4
Brasília 4
Campinas 4
Chicago 4
Houston 4
Jacksonville 4
Memphis 4
Mexico City 4
New Delhi 4
Orem 4
Phoenix 4
Poggiomarino 4
Springfield 4
Warsaw 4
Aprilia 3
Baku 3
Belo Horizonte 3
Charlotte 3
Chennai 3
Columbus 3
Duncan 3
Edinburgh 3
González Catán 3
Haiphong 3
Hangzhou 3
Kuala Lumpur 3
Mar del Plata 3
Nairobi 3
Nha Trang 3
Norwalk 3
Nova Iguaçu 3
Paris 3
Porto Alegre 3
Pune 3
Rio de Janeiro 3
Tbilisi 3
Turin 3
Assago 2
Barbacena 2
Bauru 2
Bogotá 2
Bourne End 2
Brussels 2
Budapest 2
Cairo 2
Camaçari 2
Campo Grande 2
Can Tho 2
Totale 4.990
Salva come PNG Salva come JPEG
Nome #
Mitochondrial transfer from Adipose stem cells to breast cancer cells drives multi-drug resistance 871
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells 718
Adipose Stem Cells and Their Interplay with Cancer Cells and Mitochondrial Reservoir: A New Promising Target 474
null 417
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 336
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy 276
Anti-PD1 therapy effects on T cell repertoire and functions in patients with NSCLC cancer: a preliminary study to identify biomarkers of efficacy 132
Role of the Hedgehog pathway in preventing occurrence of resistance to first, second, third generation EGFR-TKIs in first line therapy of NSCLC models with EGFR activating mutations 131
A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial 123
Decoding chromosomal instability insights in CRC by integrating omics and patient-derived organoids 98
Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer 89
Implication of the Hedgehog pathway in hepatocellular carcinoma 84
"Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction" 82
Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development 73
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy 71
Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress 70
A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo 69
Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation 68
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 68
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 66
Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo 66
Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study 66
MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer 65
Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer 64
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy 64
Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells 64
Efficacy of osimertinib in combination with Hedgehog pathway inhibitors in reverting T790M-mediated resistence 63
Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization 60
Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells 57
Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer 57
In the literature: August 2018 55
ZNF518B as a transcriptional factor involved in colorectal cancer progression through the epithelial to mesenchymal transition 51
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer 51
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 51
Circulating cancer stem cells: an interesting niche to explore 50
Insulitis in Human Type 1 Diabetic Pancreas: From Stem Cell Grafting to Islet Organoids for a Successful Cell-Based Therapy 50
NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances 50
Novel applications of liquid Biopsy: Comprehensive methodology for circulating biomarker exploration in peripheral blood 48
How organoids can improve personalized treatment in patients with gastro-esophageal tumors 48
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 47
Stemness markers of osteosarcoma 47
Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer 47
Efficacy of second and third generation EGFR tyrosine kinase inhibitors, alone or in combination, in T790M-mediated resistance 44
Patient-derived organoids as a tool for modelling localized colorectal cancer 44
Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis 44
3D patient-derived gastric cancer organoids as a tool for functional precision medicine for gastric cancer patients 43
Development of a living organoid biobank derived from colorectal cancer patients: Towards personalized medicine 43
Effect of MEK inhibition on PD-L1 and MCH-1 expression and on cytokines production profile in NSCLC cells and in human lymphocites 41
Effect of MEK inhibition on PDL1 and and on cytokinesproduction profilein NSCLC cell lines and in human lymphocites 41
A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC 40
The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer 39
CNAs concordance between CRC-PDOs and the original tissue reveals relevant oncogenic pathways alterations 39
Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype 37
Anti-PD1 therapy effects on T cell repertoire and functions in patients with NSLC cancer: a preliminary study to identify biomarkers of efficacy 37
Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. 36
Synergistic effects of oncogene inhibition and pyruvate dehydrogenase kinase blockade in resistant NSCLC cells 35
Metastatic colorectal cancer derived organoids recapitulate genomic profile and treatment response of the original tumor 35
Efficacy of sequential treatment with first, second and third generation EGFR inhibitors and role of Hedgehog pathway in the acquisition of resistance in in vivo NSCLC models 33
New insights from KISS activity: a prognostic biomarker in malignant pleural mesothelioma 32
An integrated analysis of gene expression profile and chromosomal aberrations highlighted the oxidative stress role in anti-HER2 drug-resistant gastric cancer models 32
Prognostic nutritional index (PNI) is an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer (LAHNSCC) 30
Will Organoids Fill the Gap towards Functional Precision Medicine? 30
Reversion of mesenchymal behaviour by AZD9291 (osimertinib) in EGFR mutant NSCLC cell lines resistant to first generation EGFR tyrosine kinase inhibitors 28
Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 28
Met/Axl system as a dual target in the mesothelioma pathway and invasiveness 26
Results of safety run-in part in Metal (METformin in Advanced Lung cancer) trial 24
Synergistic effect of vismodegib and cisplatin in NSCLC models via autophagy 22
Totale 6.420
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.809
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.809
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213 0 0 0 0 0 0 0 0 0 0 0 3
2021/2022127 3 0 2 0 1 0 0 10 26 0 16 69
2022/2023370 26 0 6 42 46 72 6 52 83 2 30 5
2023/2024202 7 14 10 4 10 34 4 8 28 2 9 72
2024/2025630 8 24 37 17 27 76 107 34 95 40 72 93
2025/20264.998 841 1.388 1.215 79 257 94 481 104 132 247 97 63
Totale 6.420